Skip to main content
. 2020 Jul 31;12(8):2132. doi: 10.3390/cancers12082132

Figure 3.

Figure 3

Tornado diagram for the one-way sensitivity analysis of variables influencing LYG of advanced HCC patients treated with Lenvatinib-Nivolumab (A) or Atezolizumab plus Bevacizumab-Nivolumab (B). Both were compared to the Sorafenib-Nivolumab treatment.